HSP90AA1 and cancer: Treatment of MDA-MB-468 epichaperome-high cancer cells with these inhibitors resulted in a dose-dependent decrease in epichaperomes, as observed by native PAGE coupled with immunoblotting against epichaperome components such as HSP90α, HSP90β, HSC70, CDC37, HOP, and HSP110.